Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI). The study found that BI 764524 was well tolerated following intravitreal administration of single and ...

Related Keywords

Ingelheim , Rheinland Pfalz , Germany , Quan Dong Nguyen , Ulrike Graefe Mody , Boehringer Ingelheim , Animal Health , Head Of Retinal Health At Boehringer Ingelheim , Association For Research , Pediatrics At Stanford School Of Medicine , Byers Eye Institute , Stanford School , Coordinating Investigator , Retinal Health , Human Pharma , Corporate Headquarters , Ophthalmol Vis Sci ,